StockTipsArenaBeta

BUY Glenmark Pharmaceuticals — Rahul Sharma, JM Financial

BUYGlenmark Pharmaceuticals
Glenmark Pharmaceuticals share price target & all analyst calls

byRahul Sharma, JM FinancialHorizon: 1–3 months23 Sept 2026via CNBC Awaaz.

Entry₹2,464.4Inferred
Target₹2,600
Total upside +5.50% (call closed)
Stop lossNot given
Exit₹2,6006 Nov 2026, 11:14 am
Target hit+5.50%0.00%upside left
Follow Rahul Sharma for new calls(37% target hit, 38 closed calls)Get alertsWatch GLENMARK for new buy/sell callsGet alertsSee 84 active Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 6 Nov 2026
17 supporting6 neutral2 opposing
Supports the BUY call (17)

Glenmark Pharma shares will react to better-than-expected US sales in Q2, 14% growth in India biz

NewsCnbc-Tv18·6 Nov · today

(opens in new tab)

2 advisors have active long-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · adjacent horizon·3 Nov · 2d ago

Glenmark stock: US distribution hub expands supply chain

NewsGoogle News·30 Oct · 1w ago

(opens in new tab)
Neutral / worth noting (6)

Glenmark Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

NSE · Outcome of Board Meeting·5 Nov · today

(opens in new tab)

Ichnos Glenmark Innovation will present updated clinical data for ISB 2001 at the 68th ASH Annual Meeting.

BSE · Company Update·4 Nov · yesterday

(opens in new tab)
Weighs against the BUY call (2)

Glenmark Pharma Q2 Results: Net profit plunges 56% to Rs 264 crore, revenue down at Rs 4,247 cr

NewsEt-Markets·5 Nov · today

(opens in new tab)

1 advisor has an active long-term SELL call on this stock

Advisor consensus · adjacent horizon·3 Feb · 9mo ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Glenmark Pharmaceuticals

All analyst calls on Glenmark Pharmaceuticals

More from Rahul Sharma, JM Financial

Every call and its outcome